Cargando…

Correction to: Pluripotent Stem Cell-Based Screening Identifies CUDC-907 as an Effective Compound for Restoring the In Vitro Phenotype of Nakajo-Nishimura Syndrome

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985107/ https://www.ncbi.nlm.nih.gov/pubmed/36565066 http://dx.doi.org/10.1093/stcltm/szac085

Ejemplares similares

Pluripotent stem cell‐based screening identifies CUDC‐907 as an effective compound for restoring the in vitro phenotype of Nakajo‐Nishimura syndrome
por: Kase, Naoya, et al.
Publicado: (2020)

Induced pluripotent stem cells representing Nakajo-Nishimura syndrome
por: Kanazawa, Nobuo, et al.
Publicado: (2019)

Nakajo-Nishimura Syndrome: The First African Case
por: Ghodbane, Nacif Eddine, et al.
Publicado: (2023)

90 Nakajo-Nishimura syndrome: a case report
por: Halima, Zerguine, et al.
Publicado: (2022)

53 Nakajo-Nishimura syndrome: the first African case
por: Ghodbane, Nacif Eddine, et al.
Publicado: (2022)

Beneficial effect of methotrexate on a case of Nakajo-Nishimura syndrome
por: Kunimoto, K, et al.
Publicado: (2015)

Nakajo–Nishimura syndrome and related proteasome-associated autoinflammatory syndromes
por: Ohmura, Koichiro
Publicado: (2019)

Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress
por: Honda-Ozaki, Fumiko, et al.
Publicado: (2018)

A Chinese case of Nakajo–Nishimura syndrome with novel compound heterozygous mutations of the PSMB8 gene
por: Jia, Tao, et al.
Publicado: (2020)

Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening
por: Liao, Wei, et al.
Publicado: (2021)

CUDC‐907 blocks multiple pro‐survival signals and abrogates microenvironment protection in CLL
por: Chen, Yixiang, et al.
Publicado: (2018)

Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic
por: Al-Mansour, Fares, et al.
Publicado: (2023)

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2021)

Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

A case of neonatal-onset autoinflammatory syndrome with a de novo PSMB9 mutation resembling Nakajo-Nishimura syndrome
por: Kinjo, N, et al.
Publicado: (2015)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
por: Tu, Tian, et al.
Publicado: (2019)

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells
por: Huegel, Julianne, et al.
Publicado: (2022)

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
por: Hu, Cheng, et al.
Publicado: (2020)

Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis
por: Zhang, Wentian, et al.
Publicado: (2020)

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2019)

Enhanced Efficacy of 5-Fluorouracil in Combination with a Dual Histone Deacetylase and Phosphatidylinositide 3-Kinase Inhibitor (CUDC-907) in Colorectal Cancer Cells
por: Hamam, Rimi, et al.
Publicado: (2017)

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2020)

Restoring one way traffic across the Roux loop: The Nakajo value
por: Rammohan, Ashwin, et al.
Publicado: (2018)

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
por: Oki, Yasuhiro, et al.
Publicado: (2017)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2020)

Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
por: Jian, Zheng, et al.
Publicado: (2022)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

Temporal changes of serum cytokine/chemokine levels in patients of Nakajo-Nishimra syndrome treated with tocilizumab
por: Kanazawa, N, et al.
Publicado: (2015)

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)

CUDC-101 is a potential target inhibitor for the EGFR-overexpression bladder cancer cells
por: Wang, Zhenxing, et al.
Publicado: (2023)

Correction: An In Vitro Mechanism Study on the Proliferation and Pluripotency of Human Embryonic Stems Cells in Response to Magnesium Degradation
por: Nguyen, Thanh Yen, et al.
Publicado: (2014)

Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity
por: Chougule, Anuradha, et al.
Publicado: (2013)

907. Age-stratified seroprevalence of respiratory syncytial virus in Korean population
por: Nham, Eliel, et al.
Publicado: (2023)

Correction to: Class II resin composite restorations—tunnel vs. box-only in vitro and in vivo
por: Preusse, Peter J., et al.
Publicado: (2021)

Publisher Correction: Tracing the transitions from pluripotency to germ cell fate with CRISPR screening
por: Hackett, Jamie A., et al.
Publicado: (2018)

Correction: DNA Repair in Human Pluripotent Stem Cells Is Distinct from That in Non-Pluripotent Human Cells
por: Luo, Li Z., et al.
Publicado: (2012)

Correction: DNA Repair in Human Pluripotent Stem Cells Is Distinct from That in Non-Pluripotent Human Cells
por: Luo, Li Z., et al.
Publicado: (2012)

Correction: DNA Repair in Human Pluripotent Stem Cells Is Distinct from That in Non-Pluripotent Human Cells
por: Luo, Li Z., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kn7570u3c3i8cuvkca0qnr130l